https://www.cardiolrx.com/cardiol-therapeutics-to-advance-cardiolrx-into-a-late-stage-trial-in-patients-with-recurrent-pericarditis/
https://www.jazzpharma.com/science/pipeline
https://www.kiniksa.com/pipeline
https://www.cardiolrx.com/clinical-trials/acute-myocarditis/
https://www.cardiolrx.com/clinical-trials/recurrent-pericarditis/
https://www.cardiolrx.com/wp-content/uploads/2024/10/Cardiol-Therapeutics-Inc.-%E2%80%93-Corporate-Presentation_October-2024.pdf
https://www.cardiolrx.com/cardiol-therapeutics-achieves-target-patient-enrollment-in-its-phase-ii-archer-trial-investigating-cardiolrx-for-acute-myocarditis/
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-10.0-Million-Private-Placement/default.aspx
https://www.anavex.com/post/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phase-2-study
https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-present-data-reinforcing-efficacy
https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-completes-enrollment-clinical-outcomes
https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-release-third-quarter-2024-financial
https://ir.altimmune.com/news-releases/news-release-details/altimmune-present-new-data-lipidomic-profile-subjects-treated
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-third-quarter-2024-financial-results
https://ir.vikingtherapeutics.com/2024-10-16-Viking-Therapeutics-to-Report-Financial-Results-for-Third-Quarter-2024-on-October-23,-2024
